麻豆传媒视频网站

Haematology - Multiple Myeloma

A LIST OF OUR EARLY PHASE听Haematology (Multiple myeloma) TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALS

To find more information on 麻豆传媒视频网站H Early Phase Cancer Clinical Trials, including eligibility criteria, click the听hyperlinked听Local Project Reference (LRP)听ID, which will take you to the 麻豆传媒视频网站H Find a 麻豆传媒视频网站 database.

听

ProMMise A Platform trial for Relapsed patients to evaluate Ongoing novel therapies in Multiple Myeloma In combination with Standard of care therapies
Local Project Reference:
Principal Investigator:	Dr. Rakesh Popat
Drug Class/ Treatment:	Benlantamab Mafodotin (Anti-BCMA IgG1 Antibody-Drug Conjugate)
Patient Population:	Multiple Myeloma
Trial Hosted By - NIHR 麻豆传媒视频网站H Clinical Research Facility (CRF)

DTP3 Treating Multiple Myeloma and Diffuse Large B Cell Lymphoma by Targeting the NF魏B Pathway with the First-in-Class GADD45尾/MKK7 Inhibitor, DTP3
Local Project Reference:
Principal Investigator:	Dr Rakesh Popat
Drug Class/ Treatment:	DTP3听(GADD45尾/MKK7 Inhibitor)
Patient Population:	Multiple Myeloma
Trial Hosted By - NIHR 麻豆传媒视频网站H Clinical Research Facility (CRF)

79635322MMY1001 Phase 1, First-in-Human, Dose Escalation 麻豆传媒视频网站 of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma
Local Project Reference:
Principal Investigator:	Dr Rakesh Popat
Drug Class/ Treatment:	JNJ-79635322听-听Trispecific Antibody
Patient Population:	Multiple Myeloma
Trial Hosted By - NIHR 麻豆传媒视频网站H Clinical Research Facility (CRF)

TCD17710 First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell mat ration antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory lightchain amyloidosis (RRLCA)
Local Project Reference:
Principal Investigator:	Dr Rakesh Popat
Drug Class/ Treatment:	SAR445514 (NK-Cell Engager (NKCE) Targeting BCMA)
Patient Population:	Multiple Myeloma
Trial Hosted By - NIHR 麻豆传媒视频网站H Clinical Research Facility (CRF)

CAMMA - GO42552 An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 1)
Local Project Reference:
Principal Investigator:	Dr Rakesh Popat
Drug Class/ Treatment:	Cevostamab (GO425552) -听Bi-specific T-Cell Engager Arm B - Combnation with Pomalidomide + Dexamethasone
Patient Population:	Multiple Myeloma
Trial Hosted By - NIHR 麻豆传媒视频网站H Clinical Research Facility (CRF)

BGB-11417-105 A phase 1b/2 Dose-Escalation and Cohort-Expansion 麻豆传媒视频网站 to determine the Safety and Efficacy of BGB11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Local Project Reference:	听
Principal Investigator:	Dr Rakesh Popat
Drug Class/ Treatment:	BGB-11417 (BCL2 Inhibitor) Monotherapy, In Combination with Dexamethasone and In Combination with Dexamethasone/Carfilzomib
Patient Population:	Multiple Myeloma
Trial Hosted By - NIHR 麻豆传媒视频网站H Clinical Research Facility (CRF)

M24-108 A Multicenter, Phase 1b, Open-label 麻豆传媒视频网站 to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma
Local Project Reference:	听
Principal Investigator:	Dr Rakesh Popat
Drug Class/ Treatment:	ABBV-383听(B-Cell Maturation Antigen 脳 CD3 Bispecific T-Cell Redirecting Antibody)
Patient Population:	Multiple Myeloma
Trial Hosted By - NIHR 麻豆传媒视频网站H Clinical Research Facility (CRF)

听

on-hold to recruitment

CA057-003 (CC-92480) An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination 麻豆传媒视频网站 to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma
Local Project Reference:
Principal Investigator:	Dr Rakesh Popat
Drug Class/ Treatment:	Mezigdomide (CC-92480) -听Cereblon (CRBN) E3 Ligase Modulating Drug (CELMoD)
Patient Population:	Multiple Myeloma
Trial Hosted By - NIHR 麻豆传媒视频网站H Clinical Research Facility (CRF)

听

Principal Investigator(s):

Dr. rakesh popat

Consultant Haematologist